Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

Inclusion Criteria: * Diagnosis of invasive breast cancer * Resectable disease * Measurable disease, defined as a primary breast mass \> 2.0 cm by breast imaging or clinical exam * Planning to undergo surgical resection after neoadjuvant therapy * Menopausal status not specified * Eastern Clinical Oncology Group (ECOG) performance status 0-1 * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin \> 9.0 g/dL * Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2.5 times upper limit of normal (ULN) * Creatinine ≤ 1.5 times ULN * Total bilirubin ≤ 1.5 times ULN * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception Exclusion Criteria: * Intracranial disease * Hormone receptor status not specified * Obese (\> 250 pounds) * Immunosuppression from any cause (e.g., known HIV infection) * History of severe asthma and/or allergies * History of severe claustrophobia * Ferromagnetic implants, history of shotgun wound and/or shrapnel, cardiac pacemakers, or other similar situations that would be contrary to strong magnetic force * Bleeding diathesis * Unstable systemic disease, including but not limited to, any of the following: * Uncontrolled diabetes * Severe infection * Severe malnutrition * Uncontrolled hypertension * Unstable angina * Ventricular arrhythmias * Active ischemic heart disease * Congestive heart failure * Myocardial infarction within the past 6 months * Chronic liver disease * Renal disease * Active upper gastrointestinal tract ulceration * Less than 4 weeks since prior investigational drug * Prior therapy with sirolimus or its analogues * Concurrent immunosuppressive therapy (e.g., steroids, cytotoxic agents, or concurrent radiotherapy) * Concurrent anticoagulation (i.e., coumadin)